Omrix Biopharmaceuticals

We aim to develop novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs, particularly in the areas of biosurgical and passive immunotherapy products. We are utilizing our proprietary protein purification technology, innovative development capabilities, and manufacturing know-how to develop these product lines, often through collaborations with companies whose marketing and sales expertise are a complement to our own areas of specialty. Our biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. We compete in the active biosurgical hemostats market, which we believe is the fastest growing segment of the surgical sealant market. We are currently partnered with Ethicon Inc., a Johnson & Johnson Company, in the development of unique biosurgical devices which will meet critical unmet medical needs. Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications. We supply vaccinia immunoglobulin, or VIG, to several governments as a means to treat smallpox vaccine-related complications in the event of a smallpox terrorist attack . We currently market in Israel intravenous immunoglobulin, or IVIG, an antibody-based product used to treat primary immune deficiencies, as well as enriched hepatitis B immune globulin (HBIG), and we are broadening our passive immunotherapy platform by improving our current products and developing new product candidates.

Contact Details: 630 5th Avenue, 22nd Floor New York New York 10111 United States of America Tel: 212 887 6500 Fax: 212 887 6550 Email: info@omrix.com WWW: www.omrix.com/index.asp

Loading...

Recent Publications by Omrix Biopharmaceuticals:
Commercial fibrin sealants are not equivalent in a rabbit liver-resection model which quantitatively evaluates hemostasis and formation of adhesions. A rabbit partial liver resection model was used to determine the...	31st December, 2005	Omrix Biopharmaceuticals	Eur Surg Res. 2005 May-Jun;37(3):159-65. DOI Direct Link
The binding of fibrin sealant to collagen is influenced by the method of purification and the cross-linked fibrinogen-fibronectin (heteronectin) content of the 'fibrinogen' component. Two fibrinogen preparations, each an intermediate in the manufacture of...	8th July, 2005	Omrix Biopharmaceuticals, Weizmann Science Park, Nes-Ziona, Israel.	Blood Coagul Fibrinolysis. 2005 Mar;16(2):111-7.

Press Releases on Omrix Biopharmaceuticals:
Reportlinker Adds The Future of the Wound Care Management Market to 2015	10th November, 2009	Reportlinker	NEW YORK, Nov. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. The Future of the Wound Care Management Market to 2015 http://www
Johnson & Johnson Reports Full-Year and Fourth-Quarter 2008 Results	20th January, 2009	Johnson & Johnson	2008 Full-Year Sales of $63.7 Billion increased 4.3%; Full-Year EPS was $4.57 2008 Fourth-Quarter Sales of $15.2 Billion decreased 4.9%; EPS was $0.97 Excluding Special Items, 2008 Full-Year EPS was
Chiasma Provides Updates on Scientific Achievements, Financing, Management and Facilities	12th January, 2009	Chiasma, Inc.	JERUSALEM, Jan. 12 /PRNewswire/ -- Chiasma, Inc. today made the following announcements: -- Using the Company's proprietary Transient Permeability Enhancer (TPE) technology,
Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.	30th December, 2008	Johnson & Johnson	NEW BRUNSWICK, N.J., Dec. 30 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, Inc., a
Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.	27th December, 2008	Johnson & Johnson	NEW BRUNSWICK, N.J., Dec. 27 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that stockholders of Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) ("Omrix") tendered

Omrix Biopharmaceuticals Patents:
US Patent No.	Title
7125569	Removal of plasmin(ogen) from protein solutions
6113571	Applicator device for applying a multiple component fluid
6121232	Stabilized mixture comprising fibrinogen
6234994	Multicomponent tissue adhesive application device and holder for such device
6357489	Device for storing a liquid medicinal substance and method for filling an applicator for a liquid medicinal substance by use of said storing device
→View more Omrix Biopharmaceuticals patents.

Omrix Biopharmaceuticals (OMRI) Financial information Links from Barchart
OMRI Quote from from Barchart.com
OMRI Chart from from Barchart.com
OMRI Profile from from Barchart.com
OMRI Opinion from from Barchart.com
→View more Omrix Biopharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 441 times since April 2007, the link to the organisation's website has been followed 63 times

Recent Search Terms used to find this page: omrix biopharmaceuticals vaccine | omrix weizmann institute | omrix weizmann institute | omrix biopharmaceuticals | omrix biopharmaceuticals | passive hemostats johnson | passive hemostats johnson | Omrix Biopharmaceuticals | Omrix Biopharmaceuticals | Omrix Weizmann Science Park | .

Search for more companies in New York

Search for more companies in New York

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Omrix Biopharmaceuticals